Literature DB >> 25439357

Asthma phenotypes: an approach to the diagnosis and treatment of asthma.

Richard F Lockey1.   

Abstract

I teach that "Asthma is the most treatable of all chronic diseases known to mankind." Yet, outcome data from throughout the world (emergency department visits, hospitalizations, and quality of life) indicate that the diagnosis and treatment of asthma are not optimal and need improvement. Why? First, asthma is not thought of as a complex, heterogeneous disease or syndrome that consists of different phenotypes and endotypes. Second, asthma is variable, particularly in its severity, and is influenced by known, unknown, avoidable, and unavoidable environmental factors. Third, treatment usually requires complex inhalational devices that are difficult to understand and use, and with which adherence is suboptimal. Continued education on how to appropriately use medications, particularly inhaled medications, is absolutely essential, and knowledge and access to a backup treatment plan to be initiated by the patient for an asthma flare is necessary. Fourth, assessment of asthma is primarily based on symptoms, and, at times, all symptoms are due to asthma, but many times some or all symptoms are due to unrecognized and untreated comorbid or coexisting conditions. Too often, asthma is viewed as a disease that occurs in isolation, and comorbid and coexisting conditions are not appropriately identified and treated. Allergists/immunologists are well suited to provide the type of comprehensive care required to optimize asthma outcomes for the benefit of individual patients and society.

Entities:  

Mesh:

Year:  2014        PMID: 25439357     DOI: 10.1016/j.jaip.2014.09.008

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  8 in total

1.  The early detection of asthma based on blood gene expression.

Authors:  Shao-Bin Wang; Tao Huang
Journal:  Mol Biol Rep       Date:  2018-11-12       Impact factor: 2.316

2.  Asthma phenotypes: An important step for tailor-made therapy.

Authors:  Keitaro Nakamoto; Takeshi Saraya; Hajime Takizawa
Journal:  J Gen Fam Med       Date:  2017-08-31

Review 3.  Innovations in asthma therapy: is there a role for inhaled statins?

Authors:  Amir A Zeki; Mona Elbadawi-Sidhu
Journal:  Expert Rev Respir Med       Date:  2018-05-03       Impact factor: 3.772

4.  Cerium dioxide nanoparticles exacerbate house dust mite induced type II airway inflammation.

Authors:  Kirsty Meldrum; Sarah B Robertson; Isabella Römer; Tim Marczylo; Lareb S N Dean; Andrew Rogers; Timothy W Gant; Rachel Smith; Terry D Tetley; Martin O Leonard
Journal:  Part Fibre Toxicol       Date:  2018-05-23       Impact factor: 9.400

Review 5.  Asthma biomarkers in the age of biologics.

Authors:  Harold Kim; Anne K Ellis; David Fischer; Mary Noseworthy; Ron Olivenstein; Kenneth R Chapman; Jason Lee
Journal:  Allergy Asthma Clin Immunol       Date:  2017-11-17       Impact factor: 3.406

Review 6.  Mechanistic insight into the impact of nanomaterials on asthma and allergic airway disease.

Authors:  Kirsty Meldrum; Chang Guo; Emma L Marczylo; Timothy W Gant; Rachel Smith; Martin O Leonard
Journal:  Part Fibre Toxicol       Date:  2017-11-21       Impact factor: 9.400

7.  Comparison of asthma phenotypes in OVA-induced mice challenged via inhaled and intranasal routes.

Authors:  Dong Im Kim; Mi-Kyung Song; Kyuhong Lee
Journal:  BMC Pulm Med       Date:  2019-12-10       Impact factor: 3.317

8.  Implication of Cluster Analysis in Childhood Asthma.

Authors:  Min Hye Kim; Tae Bum Kim
Journal:  Allergy Asthma Immunol Res       Date:  2021-01       Impact factor: 5.764

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.